MET and non-small cell lung carcinoma: In Japanese patients who received the selective MET inhibitor capmatinib for MET exon 14 skipping advanced NSCLC in the GEOMETRY mono-1 study, ORRs of 50.0% and 36.4% were observed for treatment-naïve (n = 2) and previously treated (n = 11) Japanese patients, respectively (28).